| Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics A Menter, BE Strober, DH Kaplan, D Kivelevitch, EF Prater, B Stoff, ... Journal of the American Academy of Dermatology 80 (4), 1029-1072, 2019 | 918 | 2019 |
| Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities CA Elmets, CL Leonardi, DMR Davis, JM Gelfand, J Lichten, NN Mehta, ... Journal of the American Academy of Dermatology 80 (4), 1073-1113, 2019 | 468 | 2019 |
| Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies A Menter, JM Gelfand, C Connor, AW Armstrong, KM Cordoro, DMR Davis, ... Journal of the American Academy of Dermatology 82 (6), 1445-1486, 2020 | 313 | 2020 |
| Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures CA Elmets, NJ Korman, EF Prater, EB Wong, RN Rupani, D Kivelevitch, ... Journal of the American Academy of Dermatology 84 (2), 432-470, 2021 | 282 | 2021 |
| Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients A Menter, KM Cordoro, DMR Davis, D Kroshinsky, AS Paller, ... Journal of the American Academy of Dermatology 82 (1), 161-201, 2020 | 220 | 2020 |
| Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy CA Elmets, HW Lim, B Stoff, C Connor, KM Cordoro, M Lebwohl, ... Journal of the American Academy of Dermatology 81 (3), 775-804, 2019 | 204 | 2019 |
| Pustular psoriasis: pathophysiology and current treatment perspectives KE Benjegerdes, K Hyde, D Kivelevitch, B Mansouri Psoriasis: Targets and Therapy, 131-144, 2016 | 198 | 2016 |
| Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis J Frieder, D Kivelevitch, A Menter Therapeutic advances in chronic disease 9 (1), 5-21, 2018 | 197 | 2018 |
| Comparison of coronary artery calcium scores between patients with psoriasis and type 2 diabetes B Mansouri, D Kivelevitch, B Natarajan, AA Joshi, C Ryan, K Benjegerdes, ... JAMA dermatology 152 (11), 1244-1253, 2016 | 89 | 2016 |
| Anti‐IL‐23 and Anti‐IL‐17 biologic agents for the treatment of immune‐mediated inflammatory conditions J Frieder, D Kivelevitch, I Haugh, I Watson, A Menter Clinical Pharmacology & Therapeutics 103 (1), 88-101, 2018 | 77 | 2018 |
| Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis D Kivelevitch, B Mansouri, A Menter Biologics: Targets and Therapy, 169-182, 2014 | 73 | 2014 |
| Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis IM Haugh, AK Preston, DN Kivelevitch, AM Menter Drug Design, Development and Therapy, 3879-3883, 2018 | 69 | 2018 |
| Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities A Menter, GG Krueger, SY Paek, D Kivelevitch, IE Adamopoulos, ... Dermatology and Therapy 11, 385-400, 2021 | 62 | 2021 |
| Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas D Kivelevitch, J Frieder, I Watson, SY Paek, MA Menter Expert Opinion on Pharmacotherapy 19 (6), 561-575, 2018 | 45 | 2018 |
| Self‐medication and adherence to treatment in psoriasis DN Kivelevitch, PV Tahhan, P Bourren, NN Kogan, SE Gusis, ... International journal of dermatology 51 (4), 416-419, 2012 | 37 | 2012 |
| The impact of biologic agents on health-related quality of life outcomes in patients with psoriasis J Frieder, D Kivelevitch, CT Fiore, S Saad, A Menter Expert review of clinical immunology 14 (1), 1-19, 2018 | 28 | 2018 |
| Emerging topical treatments for psoriasis DN Kivelevitch, KR Hebeler, M Patel, A Menter Expert Opinion on Emerging Drugs 18 (4), 523-532, 2013 | 27 | 2013 |
| Palmoplantar pustular psoriasis unresponsive to the interleukin‐1β antagonist canakinumab B Mansouri, D Kivelevitch, M Campa, A Menter Clinical and Experimental Dermatology 41 (3), 324-326, 2016 | 25 | 2016 |
| Joint AAD-NPF guidelines of care for the management of psoriasis with systemic non-biological therapies A Menter, JM Gelfand, C Connor, AW Armstrong, KM Cordoro, DMR Davis, ... Journal of the American Academy of Dermatology, 2020 | 21 | 2020 |
| Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature J Frieder, D Kivelevitch, A Menter Therapeutic Delivery 8 (9), 737-746, 2017 | 20 | 2017 |
Nehal N MehtaNational Heart Lung and Blood InstituteVerified email at nih.gov